JP2019031502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019031502A5 JP2019031502A5 JP2018177184A JP2018177184A JP2019031502A5 JP 2019031502 A5 JP2019031502 A5 JP 2019031502A5 JP 2018177184 A JP2018177184 A JP 2018177184A JP 2018177184 A JP2018177184 A JP 2018177184A JP 2019031502 A5 JP2019031502 A5 JP 2019031502A5
- Authority
- JP
- Japan
- Prior art keywords
- depression
- azabicyclo
- dichlorophenyl
- enantiomer
- hexane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 206010034158 Pathological gambling Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000003028 Stuttering Diseases 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 231100000867 compulsive behavior Toxicity 0.000 claims 1
- BSMNRYCSBFHEMQ-UHFFFAOYSA-N dov-216,303 Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CNC2)C2C1 BSMNRYCSBFHEMQ-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41976910P | 2010-12-03 | 2010-12-03 | |
| US61/419,769 | 2010-12-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000485A Division JP2017114861A (ja) | 2010-12-03 | 2017-01-05 | モノアミン神経伝達物質によって影響を受ける病態の処置における（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサンの調製および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019031502A JP2019031502A (ja) | 2019-02-28 |
| JP2019031502A5 true JP2019031502A5 (enExample) | 2019-06-13 |
Family
ID=46172308
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542235A Pending JP2013544850A (ja) | 2010-12-03 | 2011-12-02 | モノアミン神経伝達物質によって影響を受ける病態の処置における（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサンの調製および使用 |
| JP2017000485A Pending JP2017114861A (ja) | 2010-12-03 | 2017-01-05 | モノアミン神経伝達物質によって影響を受ける病態の処置における（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサンの調製および使用 |
| JP2018177184A Pending JP2019031502A (ja) | 2010-12-03 | 2018-09-21 | モノアミン神経伝達物質によって影響を受ける病態の処置における（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサンの調製および使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542235A Pending JP2013544850A (ja) | 2010-12-03 | 2011-12-02 | モノアミン神経伝達物質によって影響を受ける病態の処置における（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサンの調製および使用 |
| JP2017000485A Pending JP2017114861A (ja) | 2010-12-03 | 2017-01-05 | モノアミン神経伝達物質によって影響を受ける病態の処置における（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサンの調製および使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20120258994A1 (enExample) |
| EP (1) | EP2646019A4 (enExample) |
| JP (3) | JP2013544850A (enExample) |
| KR (1) | KR20140053822A (enExample) |
| AU (1) | AU2011336318A1 (enExample) |
| BR (1) | BR112013013572A2 (enExample) |
| CA (1) | CA2834713A1 (enExample) |
| WO (1) | WO2012075473A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8519148B2 (en) | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
| JP2012500283A (ja) | 2008-08-19 | 2012-01-05 | ノップ ニューロサイエンシーズ、インク． | （ｒ）−プラミペキソールを使用した組成物並びにその方法 |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| US20140228421A1 (en) * | 2011-09-07 | 2014-08-14 | Anthony McKinney | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters |
| US20130123238A1 (en) * | 2011-11-16 | 2013-05-16 | Anthony Alexander McKINNEY | Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| WO2014113844A1 (en) * | 2013-01-28 | 2014-07-31 | Brc Operations Pty Limited | White matter diffusion tensor imaging test to predict treatment outcomes in medical treatment |
| WO2014134569A1 (en) * | 2013-02-28 | 2014-09-04 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| JP2016518406A (ja) * | 2013-05-07 | 2016-06-23 | ユーシミクス・バイオサイエンス・インコーポレイテッドＥｕｔｈｙｍｉｃｓ Ｂｉｏｓｃｉｅｎｃｅ，Ｉｎｃ． | 嗜癖障害およびアルコール関連障害を治療するための（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］へキサンの使用 |
| US9566264B2 (en) | 2013-07-01 | 2017-02-14 | Euthymics Bioscience, Inc. | Combinations and methods |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| RS67279B1 (sr) | 2013-07-12 | 2025-10-31 | Areteia Therapeutics Inc | Lečenje povišenih nivoa eozinofila i/ili bazofila |
| EP3033081B1 (en) | 2013-08-13 | 2021-05-12 | Knopp Biosciences LLC | Compositions and methods for treating chronic urticaria |
| ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
| KR20160108828A (ko) * | 2013-11-11 | 2016-09-20 | 임팩스 라보라토리즈, 인코포레이티드 | 신속하게 붕괴되는 제형 및 사용 방법 |
| CN104683094B (zh) * | 2013-11-29 | 2018-10-26 | 上海华虹集成电路有限责任公司 | 用于rsa密码的蒙哥马利阶梯算法 |
| EP3080080A4 (en) | 2013-12-09 | 2017-08-16 | Neurovance, Inc. | Novel compositions |
| PT3474844T (pt) | 2016-06-28 | 2022-11-08 | Trichomeshell Ltd | Uma forma de dosagem para ser vaporizada e fumada |
| EP3797818B1 (en) * | 2018-05-23 | 2023-01-18 | Shanghai WD Pharmaceutical Co., Ltd | Controlled-release system of active pharmaceutical ingredient and preparation method therefor |
| US11911513B2 (en) | 2018-05-23 | 2024-02-27 | Shanghai Wd Pharmaceutical Co., Ltd | Controlled-release system of active pharmaceutical ingredient and preparation method therefor |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| WO2020142545A1 (en) | 2018-12-31 | 2020-07-09 | Ethismos Research, Inc. | Novel methods |
| US11554154B2 (en) * | 2020-07-22 | 2023-01-17 | Biolite, Inc. | Polygala extract for the treatment of major depressive disorder |
| WO2023034293A1 (en) * | 2021-08-31 | 2023-03-09 | Ethismos Research, Inc. | Methods of preventing and treating pain and associated symptoms |
| CN116813547A (zh) * | 2023-06-29 | 2023-09-29 | 爱斯特（成都）生物制药股份有限公司 | 一种制备3-氮杂双环[3，2，1]辛烷盐酸盐的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| US6372919B1 (en) * | 2001-01-11 | 2002-04-16 | Dov Pharmaceutical, Inc. | (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent |
| US20070043100A1 (en) * | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| CA2619817A1 (en) * | 2004-08-18 | 2006-03-02 | Dov Pharmaceutical, Inc. | Thermodynamically stable polymorph of an azabicyclohexane |
| TW200735878A (en) * | 2005-11-18 | 2007-10-01 | Astrazeneca Ab | Pharmaceutical compositions |
| US20140228421A1 (en) * | 2011-09-07 | 2014-08-14 | Anthony McKinney | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters |
| US20130123238A1 (en) * | 2011-11-16 | 2013-05-16 | Anthony Alexander McKINNEY | Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders |
-
2011
- 2011-12-02 EP EP11844214.4A patent/EP2646019A4/en not_active Withdrawn
- 2011-12-02 WO PCT/US2011/063193 patent/WO2012075473A1/en not_active Ceased
- 2011-12-02 JP JP2013542235A patent/JP2013544850A/ja active Pending
- 2011-12-02 AU AU2011336318A patent/AU2011336318A1/en not_active Abandoned
- 2011-12-02 BR BR112013013572A patent/BR112013013572A2/pt active Search and Examination
- 2011-12-02 KR KR1020137017462A patent/KR20140053822A/ko not_active Ceased
- 2011-12-02 US US13/310,694 patent/US20120258994A1/en not_active Abandoned
- 2011-12-02 CA CA2834713A patent/CA2834713A1/en not_active Abandoned
-
2013
- 2013-06-20 US US13/923,016 patent/US20140039029A1/en not_active Abandoned
-
2017
- 2017-01-05 JP JP2017000485A patent/JP2017114861A/ja active Pending
- 2017-10-13 US US15/783,596 patent/US20180256542A1/en not_active Abandoned
-
2018
- 2018-09-21 JP JP2018177184A patent/JP2019031502A/ja active Pending
- 2018-12-28 US US16/234,874 patent/US20190358199A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/039,064 patent/US20210161863A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023076465A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| JP2008534627A5 (enExample) | ||
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| KR20250114110A (ko) | 약물 활성의 조절제로서의 부프로피온 | |
| JP2010535252A5 (enExample) | ||
| JP2007530622A5 (enExample) | ||
| JP2013544850A5 (enExample) | ||
| JP2009526751A5 (enExample) | ||
| CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
| RU2008150622A (ru) | Лечение агонистом мелатонина | |
| JP2005505539A (ja) | パーキンソン病の治療のためのｃｂ１受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物 | |
| Niaura et al. | Varenicline | |
| JP2020529995A5 (enExample) | ||
| JP2018521007A5 (enExample) | ||
| JP2005508872A5 (enExample) | ||
| JP2016501219A5 (enExample) | ||
| CN115697386A (zh) | 一种治疗帕金森病的方法和药物 | |
| JP2024503727A5 (enExample) | ||
| JP2013536837A5 (enExample) | ||
| JPWO2021029429A5 (enExample) | ||
| CN101801361A (zh) | 抑郁症的治疗 | |
| RU2006143659A (ru) | Применение ребоксетина для лечения боли | |
| JP2014534229A5 (enExample) | ||
| JP2011508727A5 (enExample) | ||
| WO2002066468A3 (en) | Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands |